Wolverine Trading, LLC Immuno Gen, Inc. Put Options Transaction History

Wolverine Trading, LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $1.47 Million - $3.52 Million	117,600 New	117,600 $3.49 Million
Q1 2020 May 11, 2020	BUY	$2.12 - $6.8 $13,144 - $42,160	6,200 Added 56.88%	17,100 $61,000
Q4 2019 Feb 12, 2020	SELL	$2.25 - $5.8 $42,750 - $110,200	-19,000 Reduced 63.55%	10,900 $55,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.39 $6,438 - $9,831	-2,900 Reduced 8.84%	29,900 $81,000
Q2 2019 Aug 20, 2019	SELL	$1.8 - $3.3 $133,560 - $244,860	-74,200 Reduced 69.35%	32,800 $71,000
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $190,872 - $468,072	79,200 Added 284.89%	107,000 $290,000
Q4 2018 Feb 14, 2019	SELL	$3.94 - $9.7 $42,946 - $105,729	-10,900 Reduced 28.17%	27,800 $125,000
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $332,820 - $435,762	38,700 New	38,700 $366,000
Q1 2018 May 15, 2018	SELL	$6.7 - $12.95 $190,950 - $369,075	-28,500 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$5.07 - $7.92 $82,134 - $128,304	-16,200 Reduced 36.24%	28,500 $183,000
Q3 2017 Nov 15, 2017	BUY	$5.4 - $8.47 $241,380 - $378,609	44,700	44,700 $342,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.